Eltrombopag Catalog No.:M10203-2 Synthetic lethal RNAi screening identifies

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

SJ000291942 induces p-SMAD1/5/8 maximally at 1hr of treatment

Viral strains that are resistant to zidovudine (AZT) or lamivudine (3TC) are generally

LDN-212320 (10 or 20 mg/kg

Chemical Name: 1-[(1R

Eltrombopag Catalog No.:M10203-2 Synthetic lethal RNAi screening identifiesEltrombopag is a small molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production. Eltrombopag was